Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics (PVLA) has 7 years of Operating Leases data on file, last reported at $375000.0 in Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $375000.0 in Q1 2026; TTM through Mar 2026 was $375000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $431000.0, changed N/A from the prior year.
• Operating Leases for Q1 2026 stood at $375000.0, down from $431000.0 in the prior quarter.
• Over the last five years, Operating Leases for PVLA reached as high as $14.4 million in Q1 2022 and fell as low as $375000.0 in Q1 2026.
• Historically, Operating Leases has averaged $9.6 million across 4 years, with a median of $12.2 million in 2022.
• Across the five-year window, Operating Leases dropped 15.42% in 2022 and declined 10.05% in 2023, its largest moves.
• Year by year, Operating Leases stood at $12.2 million in 2022, then fell by 2.66% to $11.9 million in 2023, then tumbled by 96.38% to $431000.0 in 2025, then fell by 12.99% to $375000.0 in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $375000.0 in Q1 2026, $431000.0 in Q4 2025, and $11.9 million in Q2 2023.